Glutamine Supplementation as an Anticancer Strategy: A Potential Therapeutic Alternative to the Convention.

amino acids cachexia cancer cancer therapy glutamine metabolism nutrition

Journal

Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829

Informations de publication

Date de publication:
05 Mar 2024
Historique:
received: 09 02 2024
revised: 02 03 2024
accepted: 04 03 2024
medline: 13 3 2024
pubmed: 13 3 2024
entrez: 13 3 2024
Statut: epublish

Résumé

Glutamine, a multifaceted nonessential/conditionally essential amino acid integral to cellular metabolism and immune function, holds pivotal importance in the landscape of cancer therapy. This review delves into the intricate dynamics surrounding both glutamine antagonism strategies and glutamine supplementation within the context of cancer treatment, emphasizing the critical role of glutamine metabolism in cancer progression and therapy. Glutamine antagonism, aiming to disrupt tumor growth by targeting critical metabolic pathways, is challenged by the adaptive nature of cancer cells and the complex metabolic microenvironment, potentially compromising its therapeutic efficacy. In contrast, glutamine supplementation supports immune function, improves gut integrity, alleviates treatment-related toxicities, and improves patient well-being. Moreover, recent studies highlighted its contributions to epigenetic regulation within cancer cells and its potential to bolster anti-cancer immune functions. However, glutamine implementation necessitates careful consideration of potential interactions with ongoing treatment regimens and the delicate equilibrium between supporting normal cellular function and promoting tumorigenesis. By critically assessing the implications of both glutamine antagonism strategies and glutamine supplementation, this review aims to offer comprehensive insights into potential therapeutic strategies targeting glutamine metabolism for effective cancer management.

Identifiants

pubmed: 38473414
pii: cancers16051057
doi: 10.3390/cancers16051057
pii:
doi:

Types de publication

Journal Article Review

Langues

eng

Subventions

Organisme : NCI NIH HHS
ID : P01CA233452-02
Pays : United States

Auteurs

Hayato Muranaka (H)

Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA.
Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA.

Rasaq Akinsola (R)

Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA.
Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA.

Sandrine Billet (S)

Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA.
Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA.

Stephen J Pandol (SJ)

Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA.
Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA.

Andrew E Hendifar (AE)

Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA.
Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA.

Neil A Bhowmick (NA)

Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA.
Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA.
Department of Biomedical Sciences, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA.
Department of Research, VA Greater Los Angeles Healthcare System, Los Angeles, CA 90073, USA.

Jun Gong (J)

Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA.
Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA.

Classifications MeSH